Accessibility Menu
TherapeuticsMD Stock Quote

TherapeuticsMD (NASDAQ: TXMD)

$1.15
(0.0%)
+0.00
Price as of October 21, 2025, 3:37 p.m. ET

KEY DATA POINTS

Current Price
$1.17
Daily Change
(0.0%) +$0.00
Day's Range
$1.08 - $1.24
Previous Close
$1.17
Open
$1.1
Beta
1.18
Volume
2,609
Average Volume
162,701
Market Cap
13.5M
Market Cap / Employee
$1.17M
52wk Range
$0.7 - $2.44
Revenue
-
Gross Margin
0.85%
Dividend Yield
N/A
EPS
-$0.04
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

TherapeuticsMD Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
TXMD-25.71%-98.46%-56.6%-98%
S&P+15.06%+95.03%+14.29%+437%

TherapeuticsMD Company Info

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.95M306.8%
Gross Profit$0.86M1485.2%
Gross Margin89.92%66.8%
Market Cap$13.43M-27.7%
Market Cap / Employee$13.43M0.0%
Employees10.0%
Net Income$0.55M151.9%
EBITDA-$0.60M40.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$6.07M16.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$5.72M-4.8%
Short Term Debt$0.89M-44.2%

Ratios

Q2 2025YOY Change
Return On Assets-1.38%8.9%
Return On Invested Capital-16.65%15.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$0.32M-63.8%
Operating Free Cash Flow$0.32M-63.8%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.690.370.390.50-22.48%
Price to Sales11.995.635.805.25-71.86%
Price to Tangible Book Value0.830.440.460.59-27.37%
Price to Free Cash Flow TTM13.557.5916.04-
Enterprise Value to EBITDA-28.17-56.76-17.31-23.3111.26%
Free Cash Flow Yield7.4%13.2%6.2%-
Return on Equity-14.4%-8.2%-7.7%-2.0%-87.95%
Total Debt$7.40M$7.18M$6.97M$6.60M-13.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.